PTCT
Income statement / Annual
Last year (2023), PTC Therapeutics, Inc.'s total revenue was $937.82 M,
an increase of 34.20% from the previous year.
In 2023, PTC Therapeutics, Inc.'s net income was -$626.60 M.
See PTC Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$937.82 M
|
$698.80 M
|
$538.59 M
|
$380.77 M
|
$306.98 M
|
$264.73 M
|
$194.39 M
|
$82.71 M
|
$36.77 M
|
$22.96 M
|
| Cost of Revenue |
$288.12 M |
$44.68 M |
$32.33 M |
$18.94 M |
$12.14 M |
$12.67 M |
$4.58 M |
$117.63 M |
$121.82 M |
$79.84 M |
| Gross Profit |
$649.70 M |
$654.12 M |
$506.27 M |
$361.82 M |
$294.85 M |
$252.06 M |
$189.82 M |
-$34.93 M |
-$85.05 M |
-$56.88 M |
| Gross Profit Ratio |
0.69 |
0.94 |
0.94 |
0.95 |
0.96 |
0.95 |
0.98 |
-0.42 |
-2.31 |
-2.48 |
| Research and Development
Expenses |
$666.56 M
|
$651.50 M
|
$540.68 M
|
$477.64 M
|
$257.45 M
|
$171.98 M
|
$117.46 M
|
$117.63 M
|
$121.82 M
|
$79.84 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$153.55 M
|
$121.27 M
|
$97.13 M
|
$82.08 M
|
$44.82 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$332.54 M
|
$326.00 M
|
$285.77 M
|
$245.16 M
|
$202.54 M
|
$153.55 M
|
$121.27 M
|
$97.13 M
|
$82.08 M
|
$44.82 M
|
| Other Expenses |
$10.13 M |
$116.55 M |
$54.75 M |
$36.89 M |
$27.65 M |
$129,000.00 |
-$1.28 M |
-$1.21 M |
-$465,000.00 |
-$213,000.00 |
| Operating Expenses |
$999.10 M |
$1.09 B |
$881.21 M |
$759.70 M |
$487.64 M |
$348.41 M |
$254.11 M |
$214.76 M |
$203.90 M |
$122.38 M |
| Cost And Expenses |
$1.29 B |
$1.14 B |
$913.54 M |
$778.64 M |
$499.78 M |
$361.08 M |
$258.68 M |
$214.76 M |
$203.90 M |
$122.38 M |
| Interest Income |
$0.00 |
$90.87 M |
$86.02 M |
$56.35 M |
$12.49 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$129.18 M |
$90.87 M |
$86.02 M |
$56.35 M |
-$12.49 M |
-$12.55 M |
-$12.09 M |
-$8.28 M |
-$2.37 M |
$1.18 M |
| Depreciation &
Amortization |
$236.59 M
|
$128.84 M
|
$71.52 M
|
$49.58 M
|
$36.06 M
|
$26.09 M
|
$17.68 M
|
$3.29 M
|
$2.88 M
|
$2.24 M
|
| EBITDA |
-$112.81 M
|
-$372.58 M
|
-$378.07 M
|
-$227.82 M
|
-$116.79 M
|
-$54.13 M
|
-$48.91 M
|
-$132.06 M
|
-$167.13 M
|
-$99.41 M
|
| EBITDA Ratio |
-0.12 |
-0.53 |
-0.7 |
-0.6 |
-0.38 |
-0.2 |
-0.25 |
-1.6 |
-4.55 |
-4.33 |
| Operating Income Ratio
|
-0.37
|
-0.63
|
-0.7
|
-1.04
|
-0.63
|
-0.44
|
-0.33
|
-1.6
|
-4.55
|
-4.33
|
| Total Other
Income/Expenses Net |
-$346.71 M
|
-$147.56 M
|
-$143.40 M
|
-$5.06 M
|
-$47.13 M
|
-$19.21 M
|
-$1.28 M
|
-$1.21 M
|
-$465,000.00
|
-$213,000.00
|
| Income Before Tax |
-$696.11 M |
-$587.49 M |
-$518.34 M |
-$402.93 M |
-$239.93 M |
-$128.11 M |
-$77.67 M |
-$141.54 M |
-$169.96 M |
-$98.45 M |
| Income Before Tax Ratio
|
-0.74
|
-0.84
|
-0.96
|
-1.06
|
-0.78
|
-0.48
|
-0.4
|
-1.71
|
-4.62
|
-4.29
|
| Income Tax Expense |
-$69.51 M |
-$28.47 M |
$5.56 M |
$35.23 M |
$11.65 M |
-$29,000.00 |
$1.34 M |
$569,000.00 |
$485,000.00 |
-$4.69 M |
| Net Income |
-$626.60 M |
-$559.02 M |
-$523.90 M |
-$438.16 M |
-$251.58 M |
-$128.08 M |
-$79.00 M |
-$142.11 M |
-$170.45 M |
-$93.75 M |
| Net Income Ratio |
-0.67 |
-0.8 |
-0.97 |
-1.15 |
-0.82 |
-0.48 |
-0.41 |
-1.72 |
-4.64 |
-4.08 |
| EPS |
-8.37 |
-7.79 |
-7.43 |
-6.64 |
-4.27 |
-2.75 |
-2.02 |
-4.17 |
-5.07 |
-2.97 |
| EPS Diluted |
-8.37 |
-7.79 |
-7.43 |
-6.64 |
-4.27 |
-2.75 |
-2.02 |
-4.17 |
-5.07 |
-2.97 |
| Weighted Average Shares
Out |
$74.84 M
|
$71.73 M
|
$70.47 M
|
$66.03 M
|
$58.86 M
|
$46.58 M
|
$39.11 M
|
$34.04 M
|
$33.62 M
|
$31.57 M
|
| Weighted Average Shares
Out Diluted |
$74.84 M
|
$71.73 M
|
$70.47 M
|
$66.03 M
|
$58.86 M
|
$46.58 M
|
$39.18 M
|
$34.04 M
|
$33.63 M
|
$31.57 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
